Arlington Capital Partners Issues Statement Regarding Stellant Systems, Inc.

Arlington Capital Partners says Stellant is “never been stronger,” citing growth of over 20% per year and continued investment in long-term production capacity. The statement adds that Stellant complied fully with DOJ/DoD requests and is noting continued consideration of TransDigm’s interest. Overall, the message is constructive, but lacks deal/legal resolution specifics that would likely limit near-term price impact.

Analysis

For TDG, the market should treat this as an option on capital allocation rather than an earnings event. A niche RF asset would fit the company’s high-ROIC, pricing-power playbook, but the real value is only unlocked if the asset is small enough to avoid meaningful leverage creep or integration drag; otherwise the multiple expansion can disappear faster than the synergies show up. Near term, any move in TDG should be modest because the core thesis is still the aftermarket cash machine, not this transaction.

The second-order read-through is more interesting for the defense-electronics ecosystem: if a sponsor-backed RF business can still attract strategic interest, that supports valuation for other small, mission-critical microwave/EW assets and keeps PE exit windows open. Conversely, if the review gets tougher, the loser is not just the target; it raises the cost of future tuck-in M&A across the sector and may push strategics toward smaller, less visible deals. That would favor firms with internal R&D and less regulatory friction over serial acquirers.

The contrarian miss is assuming this headline is binary. The more likely path is a months-long process that only matters if it forces divestitures, price concessions, or leverage constraints; absent that, TDG should revert to trading on core organic growth and buyback capacity. Falsifiers are straightforward: a remedy-heavy review, a visibly dilutive purchase price, or any management commentary that suggests a broader M&A binge at the expense of capital returns.

Key Decisions for Investors

• Maintain TDG as a core long, but do not add aggressively on this headline alone; expected impact is 1-3 month sentiment support, not a near-term earnings revision. Add on any 2-4% pullback unless the review process shifts to remedies or the company signals a materially richer purchase price.
• If a formal filing or clearer approval path emerges, consider a small 3-6 month TDG call spread to express M&A optionality with capped downside; keep sizing modest because the deal is unlikely to move 2025-2026 EBITDA by itself.
• Set a watch item on any DOJ/DoWar second-request or divestiture language: that is the real falsifier. If the process broadens, expect a temporary multiple headwind for TDG and relative outperformance for cash-rich industrial compounders with less regulatory exposure.
• Avoid chasing defense-electronics beta until terms are visible; if the acquisition is approved cleanly, consider a basket long in niche RF/EW names that would benefit from valuation support from strategic bidding.